Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.35 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15929456 | 0.93 | DNM1 (0.32) | DNM1CYP51A1CA1CA2CA5A | |
| SCHEMBL15929412 | 0.93 | DNM1 (0.32) | DNM1CYP51A1CXCR3ALDH1A1MAPT | |
| SCHEMBL15928041 | 0.93 | DNM1 (0.32) | DNM1CYP51A1CXCR3ALDH1A1MAPT | |
| SCHEMBL15929436 | 0.93 | DNM1 (0.32) | DNM1CYP51A1CXCR3 | |
| SCHEMBL19099646 | 0.74 | LOXL2 (0.39) | CA1CA2CA5ACA9CA5B | |
| SCHEMBL22236839 | 0.74 | MEN1 (0.43) | ALDH1A1MAPT | |
| SCHEMBL22236849 | 0.74 | HDAC3 (0.33) | — | |
| SCHEMBL15928065 | 0.74 | IDO1 (0.39) | MAPT | |
| SCHEMBL15928055 | 0.74 | LMNA (0.33) | ALDH1A1MAPT | |
| SCHEMBL22479277 | 0.71 | DNM1 (0.33) | DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542267-B2 | Cryptate compounds | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2023-01-03 | — | — | US | disclosed |
| US-11535623-B2 | Cryptate compounds | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2022-12-27 | — | — | US | disclosed |
| US-20200308183-A1 | CRYPTATE COMPOUNDS | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2020-10-01 | — | — | US | disclosed |
| US-20200308182-A1 | CRYPTATE COMPOUNDS | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2020-10-01 | — | — | US | disclosed |
| US-10717741-B2 | Cryptate compounds | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2020-07-21 | — | — | US | disclosed |
| US-20140219915-A1 | CRYPTATE COMPOUNDS | AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION (AU) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308183-A1 | CRYPTATE COMPOUNDS | HCCS, SQOR, NQO1 | DNM1 4449/4885CYP51A1 112/4885CA1 221/4885 |
| US-20140219915-A1 | CRYPTATE COMPOUNDS | HCCS, SQOR, NQO1 | DNM1 4449/4885CYP51A1 112/4885CA1 221/4885 |
| US-11542267-B2 | Cryptate compounds | HCCS, SQOR, NQO1 | DNM1 4449/4885CYP51A1 112/4885CA1 221/4885 |
| US-20200308182-A1 | CRYPTATE COMPOUNDS | HCCS, SQOR, NQO1 | DNM1 4449/4885CYP51A1 112/4885CA1 221/4885 |
| US-10717741-B2 | Cryptate compounds | HCCS, SQOR, NQO1 | DNM1 4449/4885CYP51A1 112/4885CA1 221/4885 |
| US-11535623-B2 | Cryptate compounds | HCCS, SQOR, NQO1 | DNM1 4449/4885CYP51A1 112/4885CA1 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.